CANCER UPDATE: IPP-204106

RNS Number : 6464E

Immupharma PLC

11 February 2015

 

FOR IMMEDIATE RELEASE

11 FEBRUARY 2015

CANCER UPDATE: IPP-204106

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, provides an update on its lead Cancer programme - IPP-204106.

As previously stated, the Phase I/IIa clinical trial with the next generation "polyplexed Nucant" formulation taking place in three European hospitals including the prestigious Institute Jules Bordet in Belgium, has been completed. 

This Phase I/IIa study was a dose-finding adaptive study where the Nucant was associated with chondroitin sulfate, which has shown in preclinical studies a strong potentiating effect of the Nucant. The results demonstrate that the maximum tolerated dose with chondroitin sulfate was 9mg/kg. This was the primary objective of the study.

In preclinical studies it was indicated that a 1mg/kg equivalent human dose with chondroitin sulfate in a combination therapy using the cancer drug Gemcitabin demonstrated a massive reduction in tumour volume in mouse pancreatic cancer.

These Phase I/IIa results now allow ImmuPharma, from a regulatory perspective, to commence a Phase II study in pancreatic cancer using the optimum human dosage.

A further update on this new Phase II study will be given in due course.

-Ends-

For further information please contact:

ImmuPharma plc	+ 44 (0) 20 7152 4080
Dimitri Dimitriou, Chief Executive Officer
Dr Robert Zimmer, President and Chief Scientific Officer
Richard Warr, Chairman
Lisa Baderoon, Head of Investor Relations	+ 44 (0) 7721 413496
Panmure, Gordon & Co., NOMAD & Broker	[phone]
Hugh Morgan, Fred Walsh, Duncan Monteith

 

END

 

 

STREAAAFFEFSEFF